Improved survival with MEK inhibition in BRAF-mutated melanoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F12%3A00103101" target="_blank" >RIV/00843989:_____/12:00103101 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1056/NEJMoa1203421" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1203421</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1203421" target="_blank" >10.1056/NEJMoa1203421</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improved survival with MEK inhibition in BRAF-mutated melanoma

Popis výsledku v původním jazyce

Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previoustrials, MEK inhibition appeared to be promising in this population. In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2: 1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapygroup who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. Median progression-free survival was 4.8 months in

Název v anglickém jazyce

Improved survival with MEK inhibition in BRAF-mutated melanoma

Popis výsledku anglicky

Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previoustrials, MEK inhibition appeared to be promising in this population. In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2: 1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapygroup who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. Median progression-free survival was 4.8 months in

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

367

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

107-114

Kód UT WoS článku

000306270800007

EID výsledku v databázi Scopus

—